Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17125903 | RECOMBINANT ROBO2 PROTEINS, COMPOSITIONS, METHODS AND USES THEREOF | December 2020 | September 2023 | Allow | 33 | 3 | 0 | No | No |
| 17253207 | ANTI-IL-23p19 ANTIBODY AND USE THEREOF IN TREATING DISEASES | December 2020 | May 2024 | Allow | 41 | 1 | 1 | Yes | No |
| 17122243 | Treatment of Headache, Migraine and/or Photophobia Conditions Using Humanized Anti-PACAP Antibodies | December 2020 | November 2023 | Allow | 35 | 1 | 1 | Yes | No |
| 17058537 | METHODS FOR TREATMENT OF PSORIASIS WITH AN ANTI-APO B100 ANTIBODY | November 2020 | February 2024 | Allow | 39 | 1 | 1 | Yes | No |
| 17058508 | METHODS FOR TREATMENT OF RHEUMATOID ARTHRITIS AND ACCELERATED ATHEROSCLEROSIS WITH AN ANTI-APO B100 ANTIBODY | November 2020 | February 2023 | Allow | 27 | 1 | 1 | Yes | No |
| 16953443 | A Screening Method for Identifying Anti-PACAP Antibodies or Antibody Fragments Suitable for Use in Treating or Preventing PACAP-Associated Photophobia or Light Aversion | November 2020 | January 2024 | Allow | 38 | 2 | 1 | Yes | No |
| 16951650 | METHODS OF INHIBITING INTEGRIN ALPHA9BETA1 ACTIVITY | November 2020 | June 2023 | Allow | 31 | 2 | 1 | No | No |
| 16951458 | FLT3L-FC FUSION PROTEINS | November 2020 | May 2021 | Allow | 6 | 1 | 0 | No | No |
| 17083917 | METHODS FOR ALTERING BODY COMPOSITION BY ADMINISTERING ANTI-PRO/LATENT MYOSTATIN ANTIBODIES | October 2020 | January 2024 | Allow | 39 | 3 | 1 | No | No |
| 17051678 | USE OF EPITHELIAL MEMBRANE PROTEIN 2 [EMP2] TARGETING AGENTS IN TREATING LUNG DISORDERS | October 2020 | September 2023 | Allow | 35 | 2 | 1 | Yes | No |
| 17080626 | ANTAGONISTIC CD40 MONOCLONAL ANTIBODIES AND USES IN TREATING IMMUNE RESPONSES | October 2020 | October 2021 | Allow | 11 | 2 | 1 | No | No |
| 17050261 | TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRBeta ANTIBODY | October 2020 | April 2023 | Abandon | 30 | 1 | 1 | No | No |
| 17049739 | SELECTING PATIENTS FOR THERAPY WITH ADENOSINE SIGNALING INHIBITORS | October 2020 | May 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17071931 | ANTIBODY THAT BINDS XENOPUS WISE PROTEIN | October 2020 | March 2023 | Abandon | 29 | 2 | 0 | No | No |
| 17045398 | SPNS2 NEUTRALIZING ANTIBODY | October 2020 | January 2023 | Allow | 28 | 1 | 1 | Yes | No |
| 17031965 | METHODS FOR TREATING LATE-ONSET ASTHMA USING BENRALIZUMAB | September 2020 | June 2024 | Abandon | 44 | 1 | 1 | No | No |
| 17040468 | ANTI-BAG3 ANTIBODIES AS THERAPEUTIC REAGENT IN CARDIOVASCULAR DISEASE | September 2020 | August 2022 | Abandon | 23 | 1 | 0 | No | No |
| 17019722 | ETANERCEPT FORMULATIONS STABILIZED WITH XYLITOL | September 2020 | November 2022 | Abandon | 26 | 1 | 1 | No | No |
| 16957328 | MONOCLONAL ANTIBODIES THAT BIND TRBV9 AND METHODS FOR USING SAME FOR INHIBITING THE T CELL RECEPTOR FOR TREATMENT | September 2020 | October 2022 | Allow | 28 | 1 | 1 | Yes | No |
| 16978807 | FHUD2 FUSION PROTEINS FOR THE OUTER MEMBRANE VESICLE (OMV) DELIVERY OF HETEROLOGOUS POLYPETIDES AND IMMUNOGENIC COMPOSITIONS THEREOF | September 2020 | March 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 16996623 | METHODS OF LOWERING TRIGLYCERIDE LEVELS WITH AN ANGPTL8-BINDING ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF | August 2020 | October 2022 | Allow | 26 | 1 | 1 | No | No |
| 16988257 | BIOPHARMACEUTICAL COMPOSITIONS COMPRISING NUCLEIC ACIDS ENCODING IL-5 BINDING PROTEINS | August 2020 | December 2023 | Allow | 41 | 2 | 0 | Yes | No |
| 16968528 | IMMUNOMODULATING AND IMMUNOSTIMULATING ECOTIN POLYPEPTIDES FROM SALMONELLA FOR DRUG-DELIVERY | August 2020 | May 2022 | Allow | 22 | 1 | 1 | Yes | No |
| 16985708 | METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST ANTIBODY | August 2020 | May 2024 | Allow | 45 | 1 | 1 | No | No |
| 16943289 | METHODS FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY WITH FOLLISTATIN POLYPEPTIDES | July 2020 | July 2022 | Allow | 23 | 1 | 0 | No | No |
| 16965687 | ANTI-TIGIT ANTIBODY AND USE THEREOF | July 2020 | March 2022 | Allow | 20 | 1 | 0 | No | No |
| 16919124 | METHODS FOR TREATING PSORIASIS WITH ANTAGONISTIC ANTI-LEPTIN RECEPTOR ANTIBODIES | July 2020 | December 2023 | Abandon | 41 | 4 | 0 | No | No |
| 16946483 | Methods for Using Anti-Myostatin Antibodies | June 2020 | April 2022 | Allow | 22 | 1 | 0 | No | No |
| 16909361 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING PATHOLOGICAL FIBROBLAST CELLS | June 2020 | March 2023 | Abandon | 32 | 0 | 1 | No | No |
| 16954763 | FGF21 and GLP1 DOUBLE GENE-MODIFIED MESENCHYMAL STEM CELL AND USE IN TREATING A METABOLIC DISEASE | June 2020 | April 2023 | Allow | 34 | 1 | 1 | Yes | No |
| 16772917 | TREATMENT OF MONOGENIC DISEASES WITH AN ANTI-CD45RC ANTIBODY | June 2020 | February 2023 | Abandon | 32 | 1 | 1 | No | No |
| 16772150 | ASTROTACTIN1-BASED COMPOSITIONS AND PHARMACEUTICAL FORMULATIONS | June 2020 | March 2022 | Allow | 21 | 1 | 1 | No | No |
| 16897935 | NATRIURETIC PEPTIDE RECEPTOR 1 ANTIBODIES AND METHODS OF USE | June 2020 | March 2021 | Allow | 9 | 1 | 1 | Yes | No |
| 16891344 | USING NUCLEIC ACIDS ENCODING NAP-2 POLYPEPTIDES TO IMPROVE CARDIAC FUNCTION | June 2020 | April 2022 | Allow | 22 | 1 | 0 | No | No |
| 16888249 | ANGIOPOIETIN-LIKE PROTEIN 8 POLYPEPTIDE FRAGMENTS AND COMPOSITIONS THEREOF | May 2020 | May 2022 | Abandon | 23 | 0 | 1 | No | No |
| 16882707 | METHODS OF INCREASING SATELLITE CELL PROLIFERATION WITH VORINOSTAT OR BOSUTINIB | May 2020 | April 2022 | Allow | 23 | 1 | 0 | No | No |
| 16760457 | IMMUNOTHERAPEUTIC METHOD FOR TREATING LUNG CANCER BY ADMINISTERING A POLYPEPTIDE COMPRISING AN EPITOPE OF hZP3 | April 2020 | July 2023 | Allow | 39 | 2 | 1 | No | No |
| 16861897 | NUCLEIC ACIDS ENCODING ANTI-HcTNT-N69 ANTIBODIES | April 2020 | February 2022 | Allow | 22 | 1 | 1 | Yes | No |
| 16759331 | INHIBITION OF OXIDATION-SPECIFIC EPITOPES TO TREAT ISCHEMIC REPERFUSION INJURY | April 2020 | September 2023 | Allow | 41 | 4 | 1 | Yes | No |
| 16858154 | METHODS FOR CARDIAC TISSUE REPAIR WITH COMPOSITIONS COMPRISING CTGF | April 2020 | October 2022 | Allow | 29 | 1 | 1 | Yes | No |
| 16851287 | METHODS FOR TREATING PULMONARY HYPERTENSION WITH A LIGAND BINDING DOMAIN OF A TGF-BETA TYPE II RECEPTOR | April 2020 | July 2023 | Allow | 39 | 2 | 1 | No | No |
| 16755268 | Compositions and Methods Using a Single-Domain Antibody Binding Transferrin and Protein A for Increasing Protein Half-life in Serum | April 2020 | August 2022 | Allow | 28 | 1 | 1 | Yes | No |
| 16838711 | USE OF SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR LEVELS IN THE MANAGEMENT OF PATIENTS WITH CARDIOVASCULAR DISEASE | April 2020 | March 2022 | Abandon | 24 | 1 | 1 | No | No |
| 16829283 | SYNTHETIC TRUNCATED NORRIN PROTEIN | March 2020 | September 2021 | Allow | 17 | 1 | 0 | Yes | No |
| 16648130 | ANTI-FOLATE RECEPTOR ALPHA ANTIBODY CONJUGATED WITH HEMIASTERLINS | March 2020 | April 2024 | Allow | 49 | 1 | 2 | Yes | No |
| 16818149 | METHOD FOR TREATING CANCER WITH C-KIT ANTIBODIES | March 2020 | February 2022 | Allow | 24 | 1 | 1 | No | No |
| 16646994 | MELANIN ANTIBODIES AND USES THEREOF | March 2020 | May 2023 | Allow | 38 | 1 | 1 | Yes | No |
| 16816097 | NUCLEIC ACID MOLECULES ENCODING CLOSTRIDIUM HISTOLYTICUM COLLAGENASE I AND METHODS OF PRODUCING THE SAME | March 2020 | March 2024 | Allow | 48 | 1 | 1 | No | No |
| 16641889 | USE OF CANAKINUMAB | February 2020 | April 2023 | Abandon | 37 | 0 | 1 | No | No |
| 16641897 | USE OF CANAKINUMAB | February 2020 | May 2023 | Abandon | 38 | 0 | 1 | No | No |
| 16798953 | COMPOSITION FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE COMPRISING A cDNA ENCODING BMI-1 | February 2020 | March 2024 | Abandon | 49 | 3 | 1 | No | No |
| 16798269 | INTERLEUKIN 15 FUSION PROTEIN FOR TUMOR TARGETING THERAPY | February 2020 | September 2021 | Allow | 19 | 2 | 1 | Yes | No |
| 16793643 | ANTIBODIES AGAINST CD38 FOR TREATMENT OF MULTIPLE MYELOMA | February 2020 | September 2023 | Abandon | 43 | 1 | 1 | No | No |
| 16639424 | Methods Of Treating Cancer By Inhibiting SETD2 | February 2020 | December 2023 | Allow | 46 | 2 | 1 | No | No |
| 16787313 | HUMANIZED ANTI-PACAP ANTIBODIES | February 2020 | December 2020 | Allow | 10 | 1 | 1 | No | No |
| 16787260 | HUMANIZED ANTI-PACAP ANTIBODIES | February 2020 | October 2020 | Allow | 9 | 1 | 1 | Yes | No |
| 16787294 | ANTI-PACAP ANTIBODIES | February 2020 | December 2020 | Allow | 10 | 2 | 1 | No | No |
| 16787250 | HUMANIZED ANTI-PACAP ANTIBODIES | February 2020 | November 2020 | Allow | 9 | 1 | 1 | No | No |
| 16637383 | METHOD FOR PREVENTING OR TREATING ATHEROSCLEROSIS | February 2020 | June 2021 | Abandon | 16 | 1 | 1 | No | No |
| 16782015 | KIT FOR DETECTING CORONARY ARTERY DISEASE COMPRISING AN MAA PROTEIN ADDUCT AND REAGENTS THAT BIND TO ANTIBODIES | February 2020 | September 2022 | Allow | 31 | 1 | 1 | Yes | No |
| 16635687 | EXOSOMES DERIVED FROM CORTICAL BONE STEM CELLS CAN AUGMENT HEART FUNCTION AFTER CARDIAC INJURY | January 2020 | March 2024 | Abandon | 49 | 2 | 1 | No | No |
| 16635526 | ANTI-CD39 ANTIBODIES | January 2020 | January 2022 | Allow | 24 | 1 | 1 | Yes | No |
| 16748057 | LONG-ACTING G-CSF FOR PREVENTING NEUTROPENIA OR REDUCING DURATION OF NEUTROPENIA | January 2020 | August 2023 | Allow | 42 | 3 | 1 | Yes | No |
| 16631756 | METHOD FOR PREDICTION OF RESPONSE TO CARDIOVASCULAR REGENERATION BASED ON DETECTING THE AMOUNT OF BIOMARKERS | January 2020 | March 2023 | Allow | 38 | 2 | 1 | Yes | No |
| 16630572 | BLOCKING GARP CLEAVAGE AND METHODS OF USE THEREOF | January 2020 | May 2022 | Abandon | 28 | 0 | 1 | No | No |
| 16627075 | PHARMACEUTICAL COMPOSITION COMPRISING PCSK-9 ANTIBODY AND USE THEREOF | December 2019 | September 2022 | Allow | 33 | 2 | 1 | No | No |
| 16626071 | Inhibition of Vascular Matrix Metalloproteinase-9 to Treat Ischemic Injury | December 2019 | January 2022 | Allow | 25 | 2 | 1 | No | No |
| 16723782 | Chimeric Immunoreceptor Useful in Treating Human Cancers | December 2019 | November 2021 | Allow | 23 | 1 | 1 | No | No |
| 16714292 | ANTI-APOC3 ANTIBODIES | December 2019 | September 2021 | Allow | 22 | 1 | 1 | No | No |
| 16714294 | POLYNUCLEOTIDES ENCODING ANTI-APOC3 ANTIBODIES | December 2019 | September 2021 | Allow | 22 | 1 | 1 | No | No |
| 16707492 | METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (heFH) WITH AN ANTI-PCSK9 ANTIBODY | December 2019 | December 2021 | Allow | 24 | 2 | 1 | No | No |
| 16616435 | CMV Vaccine and Method of Making and Using the Same | November 2019 | May 2023 | Abandon | 42 | 1 | 1 | No | No |
| 16616318 | ANTIBODY-IL2 ENGRAFTED PROTEINS AND METHODS OF USE IN THE TREATMENT OF CANCER | November 2019 | September 2023 | Allow | 46 | 3 | 1 | Yes | No |
| 16687272 | A METHOD FOR THE TREATMENT OR PREVENTION OF A DISEASE RELATED TO VASCULAR ENDOTHELIAL LIPASE BY ADMINISTERING A HUMANIZED MONOCLONAL ANTIBODY | November 2019 | July 2021 | Allow | 20 | 1 | 1 | No | No |
| 16686596 | ANTAGONISTIC CD40 MONOCLONAL ANTIBODIES AND USES THEREOF | November 2019 | July 2021 | Allow | 20 | 0 | 1 | Yes | No |
| 16612958 | EX VIVO METHOD OF GENERATING SUPER REGULATORY T CELLS FOR THE PREVENTION OF AUTOIMMUNE DISEASE | November 2019 | February 2023 | Allow | 39 | 2 | 1 | Yes | No |
| 16611203 | RESOLVIN MIMETIC ANTIBODIES AND USES THEREOF | November 2019 | March 2022 | Allow | 28 | 1 | 1 | Yes | No |
| 16608519 | CELLS EXPRESSING A BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR | October 2019 | January 2022 | Abandon | 26 | 0 | 1 | No | No |
| 15777666 | HIV antibody derivatives with dual antiviral and immunomodulatory activities from CD4 and GP41 | October 2019 | August 2023 | Allow | 60 | 3 | 1 | No | No |
| 16607066 | ONCOLYTIC VIROTHERAPY WITH HELPER-DEPENDENT ADENOVIRAL-BASED VECTORS EXPRESSING IMMUNOMODULATORY MOLECULES | October 2019 | October 2023 | Allow | 47 | 2 | 1 | Yes | No |
| 16658965 | ANTI-APOC3 ANTIBODIES AND METHODS OF USE THEREOF | October 2019 | September 2021 | Allow | 23 | 0 | 1 | Yes | No |
| 16657287 | METHODS AND COMPOSITIONS FOR TREATING ULCERS | October 2019 | July 2021 | Allow | 21 | 0 | 1 | No | No |
| 16657000 | ANTI-NPR1 ANTIBODIES AND USES THEREOF | October 2019 | December 2021 | Allow | 26 | 1 | 1 | Yes | No |
| 16604378 | USE OF LAMBDA INTERFERONS IN THE TREATMENT OF OBESITY-RELATED DISORDERS AND RELATED DISEASES | October 2019 | June 2024 | Allow | 56 | 4 | 1 | Yes | Yes |
| 16592656 | IL-12 HETERODIMERIC FC-FUSION PROTEINS | October 2019 | March 2022 | Allow | 30 | 2 | 1 | Yes | No |
| 16498586 | ENGINEERED T-CELL MODULATING MOLECULES AND METHODS OF USING SAME | September 2019 | December 2022 | Abandon | 39 | 1 | 1 | No | No |
| 16498276 | NEW UNIVERSAL CHIMERIC ANTIGEN RECEPTOR T CELLS SPECIFIC FOR CD22 | September 2019 | February 2023 | Allow | 40 | 1 | 1 | No | No |
| 16580603 | METHODS FOR TREATING INFLAMMATION USING ANTIBODIES TO KALLIDIN AND DES-ARG10-KALLIDIN | September 2019 | February 2023 | Abandon | 41 | 5 | 1 | No | No |
| 16580483 | Anti-CD30 Antibodies and Methods for Treating CD30+ Cancer | September 2019 | October 2022 | Allow | 37 | 3 | 1 | Yes | Yes |
| 16580625 | CD30 Bispecific Antibodies and Method of Immunotherapy of CD30+ Malignancies | September 2019 | January 2023 | Allow | 40 | 4 | 1 | No | No |
| 16496129 | METHODS OF TREATING CANCER USING ANTI-LRP1 POLYCLONAL ANTIBODIES | September 2019 | May 2022 | Allow | 32 | 2 | 1 | Yes | No |
| 16496252 | LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5 INHIBITION SUPPRESSES TUMOR FORMATION | September 2019 | September 2022 | Abandon | 36 | 2 | 1 | No | No |
| 16575903 | METHODS OF TREATMENT OF EOSINOPHILIC BRONCHITIS WITH AN ANTI-IL-5 ANTIBODY | September 2019 | January 2022 | Allow | 28 | 2 | 1 | No | No |
| 16495633 | ANTI-TMEFF1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | September 2019 | January 2022 | Allow | 28 | 1 | 1 | No | No |
| 16493888 | METHODS AND COMPOSITIONS FOR ENHANCING CARDIOMYOCYTE MATURATION AND ENGRAFTMENT | September 2019 | April 2023 | Allow | 43 | 1 | 1 | Yes | No |
| 16488238 | IMMUNOGENIC FRAGMENT PEPTIDE OF EN2 PROTEIN OR ANTIBODY COMPOSITION SPECIFICALLY RECOGNIZING SAME | August 2019 | August 2022 | Allow | 35 | 2 | 1 | Yes | No |
| 16488082 | ACVR2A-Specific Antibody and Method of Treatment of Muscle Atrophy | August 2019 | April 2021 | Allow | 20 | 2 | 1 | Yes | No |
| 16487051 | ANTIFIBROTIC ACTIVITY OF CD47 BLOCKADE | August 2019 | November 2021 | Allow | 27 | 1 | 1 | No | No |
| 16544356 | PIP2 AS A MARKER FOR HDL FUNCTION AND CARDIOVASCULAR DISEASE RISK | August 2019 | March 2021 | Abandon | 19 | 1 | 1 | No | No |
| 16538886 | ANTIBODIES RECOGNIZING GENETIC VARIANTS OF NT-proBNP | August 2019 | February 2022 | Allow | 30 | 2 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HOWARD, ZACHARY C.
With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 13.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HOWARD, ZACHARY C works in Art Unit 1646 and has examined 900 patent applications in our dataset. With an allowance rate of 48.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 29 months.
Examiner HOWARD, ZACHARY C's allowance rate of 48.3% places them in the 12% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by HOWARD, ZACHARY C receive 1.68 office actions before reaching final disposition. This places the examiner in the 31% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by HOWARD, ZACHARY C is 29 months. This places the examiner in the 62% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +51.3% benefit to allowance rate for applications examined by HOWARD, ZACHARY C. This interview benefit is in the 93% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 23.9% of applications are subsequently allowed. This success rate is in the 37% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 50.8% of cases where such amendments are filed. This entry rate is in the 77% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 87.9% of appeals filed. This is in the 81% percentile among all examiners. Of these withdrawals, 79.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 82.4% are granted (fully or in part). This grant rate is in the 85% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 2.4% of allowed cases (in the 77% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.3% of allowed cases (in the 72% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.